STAR-ASPIRIN

Trial Acronym STAR Aspirin
Clinical Area Critical Care
Description An ICU based clinical trial to test the hypothesis that aspirin is safe and improves important surrogate clinical outcomes in adult patients with ARDS.
Status Closed
RECRUITMENT
Date Opened to Recruitment
Target Recruitment 60
Recruitment to date 30
Date Closed to Recruitment 25/11/2018
No. of Sites 4
TRIAL DESIGN
Trial Design A prospective, randomised, double-blind, allocation concealed, placebo-controlled phase 2, clinical trial in patients with ARDS.
Study Aim The aim of this study is to test the hypothesis that aspirin is safe and improves important surrogate clinical outcomes in adult patients with ARDS.

Objective 1: To conduct a randomised, double-blind, allocation concealed, placebo-controlled phase 2 trial of aspirin as a treatment for ARDS.
Objective 2: To study the biological effects of aspirin on pulmonary and systemic
a. inflammatory responses,
b. epithelial and endothelial function and injury and
c. lipid inflammatory mediators
CHIEF INVESTIGATOR (CI)
Chief Investigator Professor Danny McAuley
SPONSOR(s) & FUNDER(s)
Sponsors BHSCT
Funder The Health & Social Care Research & Development Division of the Public Health Agency, Northern Ireland.